AR113815A1 - REDUCCIÓN DEL INHIBIDOR DEL C5aR DE LA sCD163 URINARIA - Google Patents
REDUCCIÓN DEL INHIBIDOR DEL C5aR DE LA sCD163 URINARIAInfo
- Publication number
- AR113815A1 AR113815A1 ARP180103168A ARP180103168A AR113815A1 AR 113815 A1 AR113815 A1 AR 113815A1 AR P180103168 A ARP180103168 A AR P180103168A AR P180103168 A ARP180103168 A AR P180103168A AR 113815 A1 AR113815 A1 AR 113815A1
- Authority
- AR
- Argentina
- Prior art keywords
- c5ar
- reduction
- aav
- antagonist
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579716P | 2017-10-31 | 2017-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113815A1 true AR113815A1 (es) | 2020-06-17 |
Family
ID=66326509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103168A AR113815A1 (es) | 2017-10-31 | 2018-10-31 | REDUCCIÓN DEL INHIBIDOR DEL C5aR DE LA sCD163 URINARIA |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190134020A1 (https=) |
| EP (2) | EP4671767A3 (https=) |
| JP (2) | JP7789483B2 (https=) |
| KR (1) | KR20200109297A (https=) |
| CN (1) | CN111670185A (https=) |
| AR (1) | AR113815A1 (https=) |
| AU (2) | AU2018359237A1 (https=) |
| CA (1) | CA3078732A1 (https=) |
| WO (1) | WO2019089534A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11191756B2 (en) | 2018-06-07 | 2021-12-07 | Chemocentryx, Inc. | Dosing and effect of C5a antagonist with ANCA-associated vasculitis |
| WO2020112961A1 (en) | 2018-11-30 | 2020-06-04 | Chemocentryx, Inc. | Capsule formulations |
| CN114867473A (zh) * | 2019-11-08 | 2022-08-05 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
| US11603356B2 (en) | 2019-11-08 | 2023-03-14 | Chemocentryx, Inc. | Amorphous form of a complement component C5a receptor |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| CN116529241A (zh) * | 2020-10-28 | 2023-08-01 | 坎莫森特里克斯公司 | 治疗化脓性汗腺炎的方法 |
| JP7839157B2 (ja) * | 2020-10-28 | 2026-04-01 | ケモセントリックス， インコーポレイテッド | 化膿性汗腺炎を処置する方法 |
| WO2022140258A1 (en) * | 2020-12-21 | 2022-06-30 | Chemocentryx, Inc. | Treatment of c3 glomerulopathy using a c5a inhibitor |
| CA3173944A1 (en) | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| RS54998B1 (sr) | 2008-12-22 | 2016-11-30 | Chemocentryx Inc | Antagonisti c5ar |
| US20110275639A1 (en) * | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| RS56332B1 (sr) | 2010-06-24 | 2017-12-29 | Chemocentryx Inc | Antagonisti c5ar |
| DK3200791T3 (da) | 2014-09-29 | 2020-05-25 | Chemocentryx Inc | Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister |
| WO2016166357A2 (en) * | 2015-04-17 | 2016-10-20 | The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin | Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject |
| EP3439658B1 (en) * | 2016-04-04 | 2021-11-24 | ChemoCentryx, Inc. | Soluble c5ar antagonists |
-
2018
- 2018-10-30 CA CA3078732A patent/CA3078732A1/en active Pending
- 2018-10-30 US US16/174,658 patent/US20190134020A1/en not_active Abandoned
- 2018-10-30 AU AU2018359237A patent/AU2018359237A1/en not_active Abandoned
- 2018-10-30 CN CN201880070265.5A patent/CN111670185A/zh active Pending
- 2018-10-30 WO PCT/US2018/058134 patent/WO2019089534A1/en not_active Ceased
- 2018-10-30 EP EP25198900.0A patent/EP4671767A3/en active Pending
- 2018-10-30 JP JP2020523705A patent/JP7789483B2/ja active Active
- 2018-10-30 KR KR1020207015095A patent/KR20200109297A/ko not_active Ceased
- 2018-10-30 EP EP18873880.1A patent/EP3704110A4/en not_active Ceased
- 2018-10-31 AR ARP180103168A patent/AR113815A1/es unknown
-
2022
- 2022-07-29 US US17/815,992 patent/US20230105869A1/en active Pending
-
2023
- 2023-07-07 JP JP2023112051A patent/JP2023133317A/ja active Pending
-
2024
- 2024-04-19 AU AU2024202593A patent/AU2024202593A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021501159A (ja) | 2021-01-14 |
| WO2019089534A1 (en) | 2019-05-09 |
| CN111670185A (zh) | 2020-09-15 |
| KR20200109297A (ko) | 2020-09-22 |
| TW201922289A (zh) | 2019-06-16 |
| EP4671767A3 (en) | 2026-03-11 |
| US20230105869A1 (en) | 2023-04-06 |
| EP3704110A4 (en) | 2021-08-04 |
| JP2023133317A (ja) | 2023-09-22 |
| EP4671767A2 (en) | 2025-12-31 |
| US20190134020A1 (en) | 2019-05-09 |
| AU2018359237A1 (en) | 2020-04-30 |
| JP7789483B2 (ja) | 2025-12-22 |
| AU2024202593A1 (en) | 2024-05-09 |
| EP3704110A1 (en) | 2020-09-09 |
| CA3078732A1 (en) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113815A1 (es) | REDUCCIÓN DEL INHIBIDOR DEL C5aR DE LA sCD163 URINARIA | |
| CO2020000214A2 (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| CO2018010538A2 (es) | Anticuerpos específicos del receptor de poliovirus humano (rvp) | |
| CL2018000390A1 (es) | Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador | |
| AR115702A1 (es) | Moléculas agonistas biespecíficas de unión a antígeno 4-1bb | |
| AR106574A1 (es) | Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador | |
| UY36968A (es) | Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll | |
| CL2017002401A1 (es) | Anticuerpos contra icos | |
| CL2019000760A1 (es) | Tratamiento de migraña refractaria | |
| MX2022015258A (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos. | |
| MX2020004561A (es) | Anticuerpos biespecificos que se unen a alk-1 y bmpr-2. | |
| DOP2018000212A (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| MX2018004531A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
| MX2017003565A (es) | Anticuerpos anti-edad para el tratamiento de inflamacion y trastornos autoinmunes. | |
| CO2018000809A2 (es) | Anticuerpos para cd40 | |
| CU20140073A7 (es) | Composiciones y métodos para anticuerpos que actúan sobre el factor p | |
| CO2021010062A2 (es) | Inhibidores específicos del complejo de ltbp de tgfβ y usos de los mismos | |
| CR20180065A (es) | Constructos de anticuerpo biespecíficos que se unen a egfrviii y cd3 | |
| AR081750A1 (es) | Anticuerpos anti-cd40 | |
| MX2016011155A (es) | Anticuerpo que une erbb-2 y erbb-3. | |
| MX2018013072A (es) | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. | |
| AR065496A1 (es) | Anticuerpos anti- il-23 r | |
| Tola et al. | Deciphering financial contagion in the euro area during the crisis | |
| DOP2012000089A (es) | Anticuerpos monoclonales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |